Marc Tribble, MD
Internal Medicine · Dallas, TXNPI 1982669883
Payments from drug & device makers
Across 1,558 payments — averaging $445.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$531K
- Gilead$113K
- Janssen Products, LP$33K
- Theratechnologies Inc.$7K
- Merck$2K
- Johnson & Johnson$1K
- plus $4K from 31 others
What the payments were for
- Consulting fees$46,1307%
- Speaking & faculty fees$530,72677%
- Travel & lodging$80,50012%
- Food & beverage$35,5705%
- Education$4520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 750 | $531,487 |
| Gilead | 376 | $113,355 |
| Janssen Products, LP | 47 | $33,415 |
| Theratechnologies Inc. | 33 | $7,206 |
| Merck | 67 | $2,131 |
| Johnson & Johnson(2 entities) | 80 | $1,371 |
| GSK | 16 | $693 |
| AbbVie(2 entities) | 34 | $631 |
| Novo Nordisk | 28 | $540 |
| Napo Pharmaceuticals Inc | 21 | $454 |
| EMD Serono, Inc. | 24 | $381 |
| Lilly USA, LLC | 12 | $268 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $202 |
| Antares Pharma, Inc. | 11 | $182 |
| Pfizer | 9 | $169 |
| Janssen Scientific Affairs, LLC | 2 | $128 |
| Eisai Inc. | 6 | $121 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| AstraZeneca | 4 | $61 |
| Medtronic | 1 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 2 | $48 |
| Shionogi Inc | 2 | $41 |
| Verity Pharmaceuticals Inc. | 2 | $34 |
| Halozyme Inc | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $14 |
| Abiomed | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$693,378 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 239 | $1,115,352 |
| DovatoDolutegravir Sodium/Lamivudine | 286 | $896,330 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 80 | $395,313 |
| TivicayDolutegravir Sodium | 135 | $335,087 |
| JulucaDolutegravir/Rilpivirine | 70 | $282,770 |
| DescovyEmtricitabine/Tenofov Alafenam | 95 | $255,899 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 64 | $235,879 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 57 | $220,359 |
| PrezcobixDarunavir/Cobicistat | 74 | $189,716 |
| Egrifta SvTesamorelin Acetate | 19 | $180,867 |
| RukobiaFostemsavir Tromethamine | 12 | $106,391 |
| OzempicSemaglutide | 40 | $46,033 |
| MounjaroTirzepatide | 39 | $40,527 |
| Isentress HdRaltegravir Potassium | 17 | $35,560 |
| EliquisApixaban | 13 | $20,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq, Rukobia | $531,487 | $1,856,457567 claims |
| GileadBiktarvy, Descovy | $113,355 | $1,371,251334 claims |
| Janssen Products, LPSymtuza | $33,415 | $395,31380 claims |
| Johnson & JohnsonPrezcobix | $1,371 | $189,71674 claims |
| Theratechnologies Inc.Egrifta Sv | $7,206 | $180,86719 claims |
| Novo NordiskOzempic | $540 | $46,03340 claims |
| Lilly USA, LLCMounjaro | $268 | $40,52739 claims |
| MerckIsentress Hd | $2,131 | $35,56017 claims |
| PfizerEliquis, Paxlovid | $169 | $22,15826 claims |
| Antares Pharma, Inc.Xyosted | $182 | $13,61915 claims |
| AbbVieSynthroid | $631 | $1,06115 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $27 | $74566 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Dallas
- Amit VermaDallas$7.7M
- Valentine EbuhDallas$6.8M
- Gary SinclairDallas$3.4M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.